FWIW
-----Original Message----- From: Nader Pourhassan
Sent: Tuesday, April 10, 2018 12:38 PM
To: Nader Pourhassan
Subject: FW: Sorry for my emails and frustration.
FYI
-----Original Message-----
From: Nader Pourhassan
Sent: Tuesday, April 10, 2018 12:29 PM
To: 'Francis Russo' <francis.g.russo@gmail.com>; cdockery@alphaadvisorsusa.com; Michael Mulholland <mmulholland@cytodyn.com>
Subject: RE: Sorry for my emails and frustration.
Dear Francis:
I appreciate your investments in the past and I know you trusted our story that we told you and invested in CYDY.
In the last 4 years we overcame obstacles with the FDA that Progenic was not able to do so and had given up on PRO 140.
We resurrected a product that everyone pass on it (i.e. Gilead, ViiV, etc.) and in doing so we did not have the benefit of hundreds of scientist and brilliant minds as Progenic did.
We then proved to the scientific community that there is a place for PRO 140 in today's HIV space and we can get to the final approval of PRO 140 much faster than anyone thought they could (at Progenics).
We then explored other indications for PRO 140 and we were excited to see there are multiple potential for PRO 140 and our animal studies as Dr. Burger reported was stunning.
Now as an OTCB company we can't just expect to sell over 200 million shares and not have pressure on our stock. Furthermore, the path to NASDAQ has been considers several times in the past and we changed our mind due to the conditions not being favorable (in our assessment).
The good news is we have a drug that every scientist now agrees that this is approval drug (i.e. Dr. Schooley, Dr. Hammer, Dr. Maddon, see our press release with their quotes).
PRO 140 is close to the finish line and the potential for PRO 140 (market size) is in our opinion very large (in billions) and we are now trying to prove this to everyone. We were able to prove to the FDA that combination therapy is very suitable for PRO 140 and we can hit our primary endpoint and we did that. We also told the FDA 4 years ago that Monotherapy should be considered and after two years of data, the FDA agreed to give us Phase 3 investigative trial and the next step is pivotal Phase 3 providing the FDA likes the current data and we expect they will.
We also formed a community advisory board among top HIV activists and won their support.
So can we sell PRO 140 to many HIV patients starting 2019? The answer in my opinion with BTD, DEFINELTY YES.
So I am truly sorry that our stock is taking a beating but I believe we are destined to get this drug approved and that means every investor could be very happy with us and we ask for your continuous patience in these crucial times. We are fighting many battles and need all our past investors to help us now more than ever with just being fortitude so we can make you all proud of your investment.
With best regards,
Nader
Nader Pourhassan, PhD
President & CEO
CytoDyn Inc. (www.cytodyn.com)
1111 Main Street, Suite 660
Vancouver, Washington 98660
(360)980-8524 Ext. 1 - Work
(360)980-8549 - Fax
(503)348-4173-Cell
CONFIDENTIALITY NOTICE. This e-mail transmission and any documents, files, or previous e-mail messages appended or attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution, or use of the information contained or attached to this transmission is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify the sender by telephone 503-348-4173 or return e-mail message (npourhassan@cytodyn.com) and delete the original transmission, its attachments, and any copies without reading or saving in any manner. Thank you.
-----Original Message-----
From: Francis Russo [mailto:francis.g.russo@gmail.com]
Sent: Tuesday, April 10, 2018 12:10 PM
To: Nader Pourhassan <npourhassan@cytodyn.com>; cdockery@alphaadvisorsusa.com; Michael Mulholland <mmulholland@cytodyn.com>
Cc: Francis Russo <francis.g.russo@gmail.com>
Subject: Sorry for my emails and frustration.
Guys,
I sincerely wanted to apologize as I’m just a frustrated shareholder. Again I’m sorry for my emails and negative tone. In the end we share the same goal of being able to help mankind. It would be nice to see some fruits for all of the time and energy all have put into the company.
Good luck and have a good day.
Sincerely,
